LBL Biotech
www.lblbio.comLBL Biotech is developing a combination therapy treatment targeting pancreatic cancer. Our proprietary technology combines IL-20 antibody with an immune checkpoint PD-1 antibody to attenuate tumors and has delivered excellent efficacy in treating liver cancer, breast cancer, cancer-induced cachexia (CAC), chemotherapy-induced neurological disease, and spinal cord injuries.
Read more
LBL Biotech is developing a combination therapy treatment targeting pancreatic cancer. Our proprietary technology combines IL-20 antibody with an immune checkpoint PD-1 antibody to attenuate tumors and has delivered excellent efficacy in treating liver cancer, breast cancer, cancer-induced cachexia (CAC), chemotherapy-induced neurological disease, and spinal cord injuries.
Read more
Employees statistics
View all employeesPotential Decision Makers
Founder and Chief Scientific Officer
Email ****** @****.comPhone (***) ****-****
Technologies
(5)
